(Total Views: 395)
Posted On: 07/16/2025 4:50:47 PM
Post# of 155726
Many thanks for this, Ohm. Very helpful.
I'm wondering about one line in your post, and whether the CRC trial protocol is a misunderstanding of it. You write that
IFNy TEMPORARILY actives the pathway that activates PD-L1. Clearly CYDY is hoping that PD-L1 expression is not temporary, because the option to use ICIs can only happen a number of months later. Does the temporary activation of PD-L1 mean that the EXPRESSION is also temporary -- meaning that ICIs would have to be utilized at that time and not later?
I believe I've heard that some of the scientists at CYDY think that once its expression is elevated, PD-L1 will not revert. Is that true?
Thanks for weighing in on this!
I'm wondering about one line in your post, and whether the CRC trial protocol is a misunderstanding of it. You write that
Quote:
Leronlimab by increasing IFNy temporarily activates the IFNy/JAK/STAT pathway which activates PD-L1 expression.
IFNy TEMPORARILY actives the pathway that activates PD-L1. Clearly CYDY is hoping that PD-L1 expression is not temporary, because the option to use ICIs can only happen a number of months later. Does the temporary activation of PD-L1 mean that the EXPRESSION is also temporary -- meaning that ICIs would have to be utilized at that time and not later?
I believe I've heard that some of the scientists at CYDY think that once its expression is elevated, PD-L1 will not revert. Is that true?
Thanks for weighing in on this!
(8)
(0)
